Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHENZHEN STOCK EXCHANGE  >  Dong-E-E-Jiao Co Ltd    000423   CNE0000006Y9

DONG-E-E-JIAO CO LTD

(000423)
  Report  
No quotes available
-- CNY   --.--%
2016China suspends Foresea Life from selling 'universal life' insurance
RE
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (CNY)
Sales 2019 7 265 M
EBIT 2019 2 314 M
Net income 2019 2 025 M
Finance 2019 3 170 M
Yield 2019 2,47%
Sales 2020 7 826 M
EBIT 2020 2 470 M
Net income 2020 2 143 M
Finance 2020 4 002 M
Yield 2020 2,59%
P/E ratio 2019 12,82
P/E ratio 2020 12,09
EV / Sales2019 3,17x
EV / Sales2020 2,84x
Capitalization 26 220 M
More Financials
Company
Shandong Dong-E E-Jiao specializes in the manufacturing and marketing of Chinese traditional medicines and health products. The products are primarily for deficiencies in the blood, immunodeficiency, indigestion, insomnia and fatigue. All sales are in China. 
Sector
Pharmaceuticals
Calendar
06/17 | 09:00pmShareholder meeting
More about the company
Surperformance© ratings of Dong-E-E-Jiao Co Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on DONG-E-E-JIAO CO LTD
03/14CHINA RESOURCES PHARMACEUTICAL : unit Dong-E-E-Jiao year net up 2%
AQ
2016China suspends Foresea Life from selling 'universal life' insurance
RE
More news
Sector news : Alternative Medicine
05/24NOVARTIS : At $2 Million, New Novartis Drug Is Priciest Ever
DJ
05/24NOVARTIS : Correction to Novartis Article
DJ
05/24NOVARTIS : FDA Approves Novartis' Piqray for Breast Cancer
DJ
05/24NOVARTIS' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $2.12..
DJ
05/24SAMSUNG ELECTRONICS : South Korea orders further arrests at Samsung Electronics ..
RE
More sector news : Alternative Medicine
Chart DONG-E-E-JIAO CO LTD
Duration : Period :
Dong-E-E-Jiao Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 51,7  CNY
Spread / Average Target 29%
EPS Revisions
Managers
NameTitle
Yu Feng Qin President & Director
Ming Fang Chairman-Supervisory Board
Chun Cheng Wang Chairman
Jin Zhi Wang Chief Financial Officer
Huaifeng Wu Secretary, Director & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
DONG-E-E-JIAO CO LTD3 800
CANOPY GROWTH CORP63.07%15 361
AURORA CANNABIS INC65.04%8 371
BEIJING TONGRENTANG CO., LTD.7.27%5 864
CRONOS GROUP INC43.74%5 109
HUTCHISON CHINA MEDITECH LIMITED20.57%3 560